TY -的T1的有效性lacosamide单一疗法在临床实践中:了回顾性的图表总结焦癫痫患者(P5.230) JF -神经学乔-神经学六世- 88 - 16补充SP - P5.230盟-文森特维拉纽瓦盟Beatriz吉拉尔德茨AU -曼努埃尔·托莱多盟Gerrit-Jan de Haan AU -爱德华首页多Cumbo AU -安东尼奥Gambardella AU - Marc de支持者盟Lars Joeres AU -马库斯Brunnert盟-彼得Dedeken AU -穆Serratosa Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P5.230.abstract N2 -目的:评估lacosamide单药治疗的疗效和耐受性。焦癫痫患者(FS)。背景:Lacosamide FS在美国被批准作为单一疗法;缺乏从日常临床实践发表的数据。设计/方法:回顾性评估lacosamide单一疗法(第一行或转换成单一疗法)患者年龄≥16年在欧洲人一个观察点(OP) 12(±3)个月。结果包括保留率在OP 3(±3月12日),没收自由利率OP2(6±3个月)和OP3和治疗紧急药品不良反应(TEADRs)。结果:总体,包括439名患者(98一线和341转换为单药治疗;≥65岁n = 128(25一线的单方和103转换为单一疗法])。保持利率在一线和转换为单药治疗组60.2% (59/98);95%置信区间50.5 - -69.9%)和62.5% (213/341);分别为57.3 - -67.6%)。81.2%,kaplan - meier估计12个月的滞留率分别91.4%,一线和转换为单药治疗。≥65岁的病人滞留率60.0%(40.8 - -79.2%)和68.9%(60.0 - -77.9%)第一行与转换为单药治疗,分别。 At OP2, 66.3% of first line and 63.0% of conversion to monotherapy patients were seizure free (odds-ratio 1.15 [95% CI 0.713–1.839]). At OP3, 60.2% of first-line and 52.5% of conversion to monotherapy patients were seizure free (odds-ratio 1.80 [95% CI 1.080–3.001]). In patients aged ≥65 years, seizure freedom rates at OP2 were 72.0% and 68.0% for first-line and conversion to monotherapy, respectively, and at OP3, 68.0% and 56.3%, respectively. Overall, 52/439 (11.8%) patients reported TEADRs (16.4% in patients aged ≥65 years), most commonly (≥1%) dizziness (5.0%), headache (2.1%) and somnolence (1.6%).Conclusions: Lacosamide was effective and well tolerated as first-line or conversion to monotherapy for FS in a real-world clinical setting, including the subset of patients aged ≥65 years.Study Supported by: UCB PharmaDisclosure: Dr. Villanueva has received personal compensation for activities with Eisai, UCB, Bial, Novartis and Estevefor participating in advisory boards or industry-sponsored symposia. Dr Giraldez received personal compensation for activities with UCB Pharma for speaking. Dr. Toledo has received personal compensation for activities with UCB Pharma, BIAL, EISAI, Esteve, and Shire as a consultant. Dr. Toledo has received research support from EISAI and BIAL. Dr. de Haan received personal compensation for activities with UCB Pharma as as speaker and/or consultant. Dr. Cumbo has nothing to disclose. Dr. Gambardella received personal compensation from EISA and UCB for consulting, serving on a scientific advisory board, or speaking at scientific meeting,,,,,, Dr. De Backer has received personal compensation for activities with UCB Pharma as an employee. Dr. Joeres has received personal compensation for activities with UCB Pharma. Dr. Brunnert has received personal compensation for activities with UCB Biosciences GmbH as an employee. Dr. Dedeken has received personal compensation for activities with UCB Pharma as an employee. Dr Serratosa has received personal compensation for activities with UCB, Esteve, Eisai Ltd, Bial, and Cyberonics. ER -